Cuproptosis Signature Would Reveal the Acute-Remitting Pattern in Patients with Neuromyelitis Optica Spectrum Disorder
- PMID: 40810769
- DOI: 10.1002/advs.202417124
Cuproptosis Signature Would Reveal the Acute-Remitting Pattern in Patients with Neuromyelitis Optica Spectrum Disorder
Abstract
The acute-remitting course (the time interval from remission to the next relapse) is a distinct signature of neuromyelitis optica spectrum disorder (NMOSD), which harms patients and perplexes physicians. However, clinically actionable biomarkers to anticipate NMOSD relapse timing are unavailable. Recently, it is found that Cuproptosis-related genes would have an impact on the acute-remitting course in patients with aquaporin-4 (AQP4)-immunoglobulin G antibody positive NMOSD. A machine learning-based algorithm is developed to construct a consensus Cuproptosis-related prognosis risk (CRPR) model, followed by training a proportional hazards model to divide patients with NMOSD into high/low relapse risk groups. The CRPR is related to the clinical symptoms of patients with NMOSD. Finally, a nomogram is created using CRPR to predict the possibility of relapse in new cases of NMOSD. This prediction model can assist physicians and help develop appropriate interventions to prevent disease relapse.
Keywords: NMOSD; acute‐remitting course; cuprotosis.
© 2025 The Author(s). Advanced Science published by Wiley‐VCH GmbH.
Similar articles
-
Uncommon Non-MS Demyelinating Disorders of the Central Nervous System.Curr Neurol Neurosci Rep. 2025 Jul 1;25(1):45. doi: 10.1007/s11910-025-01432-8. Curr Neurol Neurosci Rep. 2025. PMID: 40591029 Review.
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Ravulizumab is Effective and Safe for Neuromyelitis Optica Spectrum Disorder Patients in Various Clinical Settings: A Single-Center Case Series with Concomitant Use of Rituximab.Cureus. 2025 May 23;17(5):e84703. doi: 10.7759/cureus.84703. eCollection 2025 May. Cureus. 2025. PMID: 40551924 Free PMC article.
-
Development of a clinical score to estimate the probability of neuromyelitis optica in patients presenting with optic neuritis.Mult Scler Relat Disord. 2025 Aug;100:106523. doi: 10.1016/j.msard.2025.106523. Epub 2025 May 13. Mult Scler Relat Disord. 2025. PMID: 40403605
-
A systematic literature review to examine the considerations around pregnancy in women of child-bearing age with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) or aquaporin 4 neuromyelitis optica spectrum disorder (AQP4+ NMOSD).Mult Scler Relat Disord. 2023 Jul;75:104760. doi: 10.1016/j.msard.2023.104760. Epub 2023 May 11. Mult Scler Relat Disord. 2023. PMID: 37224631
References
-
- a) C. Qin, M. Chen, M.‐H. Dong, S. Yang, H. Zhang, Y.‐F. You, L.‐Q. Zhou, Y.‐H. Chu, Y. Tang, X.‐W. Pang, L.‐J. Wu, D.‐S. Tian, W. Wang, Brain 2024, 147, 163;
-
- b) V. Papp, M. Magyari, O. Aktas, T. Berger, S. A. Broadley, P. Cabre, A. Jacob, J.‐I. Kira, M. I. Leite, R. Marignier, K. Miyamoto, J. Palace, A. Saiz, M. Sepulveda, O. Sveinsson, Z. Illes, Neurology 2021, 96, 59;
-
- c) S. Jarius, F. Paul, B. G. Weinshenker, M. Levy, H. J. Kim, B. Wildemann, Nat. Rev. Dis. Primers 2020, 6, 85.
-
- E. Carnero Contentti, J. Correale, J. Neuroinflamm. 2021, 18, 208.
-
- H. Y. F. Yong, J. M. Burton, Curr. Neurol. Neurosci. Rep. 2023, 23, 489.